Fax: (713) 745-1046
Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?†
Article first published online: 22 AUG 2012
Copyright © 2012 American Cancer Society
Volume 119, Issue 3, pages 477–480, 1 February 2013
How to Cite
Kim, K. B. (2013), Is there a role for targeting vascular endothelial growth factor/receptor axis in the treatment of patients with metastatic melanoma?. Cancer, 119: 477–480. doi: 10.1002/cncr.27756
See referenced original article on pages 586–92, this issue.
- Issue published online: 22 JAN 2013
- Article first published online: 22 AUG 2012
- Manuscript Accepted: 27 JUN 2012
- Manuscript Revised: 22 JUN 2012
- Manuscript Received: 4 JUN 2012
Bevacizumab and other drugs targeting vascular endothelial growth factor and/or its receptor have shown encouraging clinical outcomes in early-phase studies when they are combined with cytotoxic chemotherapy drugs. The success of bevacizumab or other antiangiogenic drugs in the treatment of patients with advanced melanoma will depend on a better understanding of tumoral neovascularization and its effect on tumor stromal tissues, as well as on selecting patients with appropriate relevant biomarkers to yield improved clinical outcomes.